Galectin Therapeutics Inc. (NASDAQ:GALT) has been given a consensus recommendation of “Hold” by the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $5.00.
A number of equities research analysts recently commented on GALT shares. ValuEngine lowered Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price (up from $6.00) on shares of Galectin Therapeutics in a research report on Thursday, December 7th. Zacks Investment Research raised Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Thursday, November 30th. Roth Capital started coverage on Galectin Therapeutics in a research report on Thursday, October 19th. They set a “buy” rating and a $8.00 target price for the company. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $5.00 target price on shares of Galectin Therapeutics in a research report on Friday, October 6th.
Galectin Therapeutics (GALT) traded up $0.08 during midday trading on Friday, reaching $2.49. The company had a trading volume of 612,773 shares, compared to its average volume of 435,412. Galectin Therapeutics has a twelve month low of $0.88 and a twelve month high of $3.68.
Several hedge funds have recently bought and sold shares of GALT. Northern Trust Corp grew its stake in shares of Galectin Therapeutics by 4.4% during the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after acquiring an additional 3,176 shares during the period. Vanguard Group Inc. grew its stake in shares of Galectin Therapeutics by 18.2% during the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after acquiring an additional 134,165 shares during the period. Advisor Group Inc. grew its stake in shares of Galectin Therapeutics by 10.4% during the 2nd quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock worth $1,191,000 after acquiring an additional 45,700 shares during the period. Finally, Virtu KCG Holdings LLC grew its stake in shares of Galectin Therapeutics by 24.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after acquiring an additional 21,008 shares during the period. Institutional investors own 11.07% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.com-unik.info/2017/12/13/brokerages-set-galectin-therapeutics-inc-galt-target-price-at-4-55.html.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
What are top analysts saying about Galectin Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galectin Therapeutics and related companies.